ClinicalTrials.gg
CompletedNCT01859988Updated Aug 28, 2017Results posted

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

A Phase 2 interventional study of Dupilumab and Placebo in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 84 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-28.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
8th of 50
380 · median 75
Started
2013
with 2 others
Phase 2
7 of 50
none open now
Registered
4th of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 3 that started in 2013, is one of 7 in phase 2, and was the 4th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Eczema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

The inclusion criteria included, but were not limited to, the following:

  1. Chronic Atopic Dermatitis that had been present for at least 3 years
  2. History of inadequate response to out-patient treatment with topical medications, or for whom topical treatments were otherwise inadvisable (e.g, because of important side effects or safety risks)
  3. Willing and able to comply with all clinic visits and study-related procedures

The exclusion criteria included, but were not limited to, the following:

  1. Prior treatment with dupilumab (REGN668/SAR231893)
  2. Presence of certain laboratory abnormalities at the screening visit
  3. Treatment with an drug within 8 weeks of baseline visit
  4. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit
  5. Certain other treatments and medical procedures undertaken within a particular time frame prior to the baseline visit
  6. Known history of (HIV) infection
  7. History of within 5 years before the baseline visit (with certain exceptions)
  8. Planned surgical procedure during the length of the study
  9. High risk of parasite infection
  10. Any other medical or psychological condition that in the opinion of the investigator or the sponsor's medical monitor, would place the participants at risk, interfere with participation in the study or interfere with interpretation of study results
  11. Pregnant or breast-feeding women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    Placebo qw

    Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection every week (qw) from Week 1 to Week 15.

    Drug: Placebo

  • Experimental
    Dupilumab 300 mg qw

    Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.

    Drug: Dupilumab

  • Experimental
    Dupilumab 300 mg q2w

    Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 15.

    Drug: Dupilumab · Drug: Placebo

  • Experimental
    Dupilumab 200 mg q2w

    Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.

    Drug: Dupilumab · Drug: Placebo

  • Experimental
    Dupilumab 300 mg q4w

    Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab every 4 weeks (q4w) and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.

    Drug: Dupilumab · Drug: Placebo

  • Experimental
    Dupilumab 100 mg q4w

    Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.

    Drug: Dupilumab · Drug: Placebo

Interventions

  • Also known as: REGN668, SAR231893, Dupixent

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved Investigator's Global Assessment (IGA) Response at Week 16

    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a static 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.

    Time frame: Week 16

  2. Percentage of Participants Who Achieved IGA Score Reduction of ≥2 at Week 16

    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic success is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score reduction from baseline of ≥2 points at Week 16 were reported. Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.

    Time frame: Week 16

  3. Percent Change in Peak Weekly Averaged Pruritus Numerical Rating Scores (NRS) From Baseline to Week 16

    Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).

    Time frame: Baseline to Week 16

  4. Absolute Change in Peak Weekly Averaged Pruritus NRS From Baseline to Week 16

    Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).

    Time frame: Baseline to Week 16

  5. Absolute Change in EASI Score From Baseline to Week 16

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

    Time frame: Baseline to Week 16

  6. Percent Change in SCORing Atopic Dermatitis (SCORAD) Scores From Baseline to Week 16

    SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Baseline to Week 16

  7. Absolute Change in SCORAD Scores From Baseline to Week 16

    SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Baseline to Week 16

  8. Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score (EASI-50, EASI-75 and EASI-90 Respectively) at Week 16

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50, EASI-75 and EASI-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in EASI score respectively from baseline to Week 16.

    Time frame: Week 16

  9. Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16

    SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). SCORAD-50, SCORAD-75 and SCORAD-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in SCORAD score respectively from baseline to Week 16.

    Time frame: Week 16

  10. Percent Change in Patient Oriented Eczema Measure (POEM) Scores From Baseline to Week 16

    POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]).

    Time frame: Baseline to Week 16

  11. Absolute Change in POEM Scores From Baseline to Week 16

    POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]).

    Time frame: Baseline to Week 16

  12. Changes in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) From Baseline to Week 16

    Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0=none, 1=mild, 2=moderate and 3=severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).

    Time frame: Baseline to Week 16

  13. Changes in GISS Cumulative Score From Baseline to Week 16

    Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none,1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).

    Time frame: Baseline to Week 16

07

Results

Posted Aug 28, 2017

Participant flow

The study was conducted at 95 study sites in 7 countries. A total of 452 participants were screened between 15 May 2013 and 10 January 2014. 380 participants were randomized and 379 were treated. 72 participants were screen failures mainly due to exclusion criteria met and inclusion criteria not met.

Participant flow — Overall Study
MilestoneDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Started636462656561
Treated636461656561
Completed525234554242
Not completed111228102319
Withdrew: Withdrawal by subject634322
Withdrew: Lack of efficacy115079
Withdrew: Physician decision131341
Withdrew: Adverse event213122
Withdrew: Lost to follow-up123032
Withdrew: Protocol violation001000
Withdrew: Other than specified above0211353

Outcome measures

PrimaryPercent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Percent change
Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16
Percent changeDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16-75.5 ± 26.86-70.5 ± 35.09-67.4 ± 31.97-64.9 ± 37.21-46.7 ± 41.96-20.2 ± 46.15
Statistical analysis
  • Dupilumab 300 mg qw vs Placebo · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Least square (ls) mean difference: -55.7 · 95% CI -68.9 to -42.4Dupilumab 300 mg qw vs Placebo
  • Dupilumab 300 mg q2w vs Placebo · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -50.1 · 95% CI -63.3 to -37.0Dupilumab 300 mg q2w vs Placebo
  • Dupilumab 200 mg q2w vs Placebo · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -47.4 · 95% CI -60.6 to -34.1Dupilumab 200 mg q2w vs Placebo
  • Dupilumab 300 mg q4w vs Placebo · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -45.4 · 95% CI -58.5 to -32.3Dupilumab 300 mg q4w vs Placebo
  • Dupilumab 100 mg q4w vs Placebo · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -26.8 · 95% CI -39.8 to -13.7Dupilumab 100 mg q4w vs Placebo
SecondaryPercentage of Participants Who Achieved Investigator's Global Assessment (IGA) Response at Week 16

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a static 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Investigator's Global Assessment (IGA) Response at Week 16
Percentage of participantsDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Percentage of Participants Who Achieved Investigator's Global Assessment (IGA) Response at Week 1633.3 (21.95 to 46.34)29.7 (18.91 to 42.42)27.9 (17.15 to 40.83)21.5 (12.31 to 33.49)12.3 (5.47 to 22.82)1.6 (0.04 to 8.80)
SecondaryPercentage of Participants Who Achieved IGA Score Reduction of ≥2 at Week 16

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic success is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score reduction from baseline of ≥2 points at Week 16 were reported. Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved IGA Score Reduction of ≥2 at Week 16
Percentage of participantsDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Percentage of Participants Who Achieved IGA Score Reduction of ≥2 at Week 1650.8 (37.89 to 63.62)46.9 (34.28 to 59.77)42.6 (30.04 to 55.94)35.4 (23.92 to 48.23)20.0 (11.10 to 31.77)9.8 (3.70 to 20.19)
SecondaryPercent Change in Peak Weekly Averaged Pruritus Numerical Rating Scores (NRS) From Baseline to Week 16

Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).

Time frame:
Baseline to Week 16
Reported as:
Mean · Percent change
Percent Change in Peak Weekly Averaged Pruritus Numerical Rating Scores (NRS) From Baseline to Week 16
Percent changeDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Percent Change in Peak Weekly Averaged Pruritus Numerical Rating Scores (NRS) From Baseline to Week 16-52.85 ± 31.368-46.22 ± 31.964-40.6 ± 33.073-38.69 ± 38.366-21.47 ± 32.952-0.43 ± 38.423
SecondaryAbsolute Change in Peak Weekly Averaged Pruritus NRS From Baseline to Week 16

Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).

Time frame:
Baseline to Week 16
Reported as:
Mean · units on a scale
Absolute Change in Peak Weekly Averaged Pruritus NRS From Baseline to Week 16
units on a scaleDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Baseline6.54 ± 1.546.74 ± 2.0726.98 ± 2.3156.84 ± 1.8536.71 ± 1.8826.34 ± 1.832
Week 163.07 ± 2.1483.64 ± 2.3884.21 ± 2.7633.99 ± 2.4495.26 ± 2.4656.05 ± 2.312
Change at Week 16-3.48 ± 2.32-3.16 ± 2.467-2.77 ± 2.595-2.79 ± 2.609-1.46 ± 2.038-0.27 ± 2.28
SecondaryAbsolute Change in EASI Score From Baseline to Week 16

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Units on a scale
Absolute Change in EASI Score From Baseline to Week 16
Units on a scaleDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Baseline30.1 ± 11.2333.8 ± 14.5232.9 ± 15.529.4 ± 11.4832.2 ± 13.4932.9 ± 13.77
Week 167.2 ± 8.8310.7 ± 12.8910.9 ± 12.419.8 ± 11.1617.4 ± 15.2825.6 ± 18.32
Change at Week 16-23.1 ± 1.70-21.1 ± 1.68-20.7 ± 1.71-20.4 ± 1.62-13.8 ± 1.64-5.8 ± 1.71
SecondaryPercent Change in SCORing Atopic Dermatitis (SCORAD) Scores From Baseline to Week 16

SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Percent change
Percent Change in SCORing Atopic Dermatitis (SCORAD) Scores From Baseline to Week 16
Percent changeDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Percent Change in SCORing Atopic Dermatitis (SCORAD) Scores From Baseline to Week 16-56.9 ± 4.12-51.2 ± 4.05-46.0 ± 4.12-48.8 ± 3.95-26.6 ± 3.98-13.8 ± 4.14
SecondaryAbsolute Change in SCORAD Scores From Baseline to Week 16

SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Absolute Change in SCORAD Scores From Baseline to Week 16
units on a scaleDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Absolute Change in SCORAD Scores From Baseline to Week 16-38.2 ± 2.76-34.4 ± 2.71-30.9 ± 2.76-33.1 ± 2.64-18.0 ± 2.66-10.5 ± 2.77
SecondaryPercentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score (EASI-50, EASI-75 and EASI-90 Respectively) at Week 16

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50, EASI-75 and EASI-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in EASI score respectively from baseline to Week 16.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score (EASI-50, EASI-75 and EASI-90 Respectively) at Week 16
Percentage of participantsDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Reduction of 50%82.5 (70.90 to 90.95)78.1 (66.03 to 87.49)62.3 (48.96 to 74.39)70.8 (58.17 to 81.40)44.6 (32.27 to 57.47)29.5 (18.52 to 42.57)
Reduction of 75%60.3 (47.20 to 72.43)53.1 (40.23 to 65.72)55.7 (42.45 to 68.45)49.2 (36.60 to 61.93)29.2 (18.60 to 41.83)11.5 (4.74 to 22.22)
Reduction of 90%36.5 (24.73 to 49.60)29.7 (18.91 to 42.42)31.1 (19.90 to 44.29)29.2 (18.60 to 41.83)15.4 (7.63 to 26.48)3.3 (0.40 to 11.35)
SecondaryPercentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16

SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). SCORAD-50, SCORAD-75 and SCORAD-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in SCORAD score respectively from baseline to Week 16.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16
Percentage of participantsDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Reduction of 50%68.3 (55.3 to 79.4)59.4 (46.4 to 71.5)52.5 (39.3 to 65.4)55.4 (42.5 to 67.7)26.2 (16.0 to 38.5)19.7 (10.6 to 31.8)
Reduction of 75%23.8 (14.0 to 36.2)25.0 (15.0 to 37.4)16.4 (8.2 to 28.1)21.5 (12.3 to 33.5)7.7 (2.5 to 17.0)3.3 (0.4 to 11.3)
Reduction of 90%6.3 (1.8 to 15.5)6.3 (1.7 to 15.2)4.9 (1.0 to 13.7)3.1 (0.4 to 10.7)3.1 (0.4 to 10.7)0.0 (0.0 to 5.9)
SecondaryPercent Change in Patient Oriented Eczema Measure (POEM) Scores From Baseline to Week 16

POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Percent change
Percent Change in Patient Oriented Eczema Measure (POEM) Scores From Baseline to Week 16
Percent changeDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Percent Change in Patient Oriented Eczema Measure (POEM) Scores From Baseline to Week 16-57.3 ± 4.52-44.0 ± 4.44-49.2 ± 5.54-46.6 ± 4.33-14.2 ± 4.350.2 ± 4.61
SecondaryAbsolute Change in POEM Scores From Baseline to Week 16

POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Absolute Change in POEM Scores From Baseline to Week 16
units on a scaleDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Absolute Change in POEM Scores From Baseline to Week 16-12.1 ± 0.88-9.8 ± 0.87-10.4 ± 0.89-9.9 ± 0.85-3.3 ± 0.85-1.1 ± 0.90
SecondaryChanges in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) From Baseline to Week 16

Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0=none, 1=mild, 2=moderate and 3=severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Changes in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) From Baseline to Week 16
units on a scaleDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Erythema-0.9 ± 0.10-0.9 ± 0.10-0.8 ± 0.10-0.8 ± 0.10-0.4 ± 0.10-0.2 ± 0.10
Infiltration/Papulation-1.2 ± 0.11-1.1 ± 0.11-1.0 ± 0.11-1.1 ± 0.10-0.6 ± 0.11-0.3 ± 0.11
Excoriations-1.4 ± 0.11-1.4 ± 0.11-1.1 ± 0.11-1.3 ± 0.11-0.6 ± 0.11-0.4 ± 0.11
Lichenification-1.1 ± 0.12-1.1 ± 0.11-1.0 ± 0.12-1.1 ± 0.11-0.7 ± 0.11-0.3 ± 0.12
SecondaryChanges in GISS Cumulative Score From Baseline to Week 16

Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none,1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Changes in GISS Cumulative Score From Baseline to Week 16
units on a scaleDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Changes in GISS Cumulative Score From Baseline to Week 16-4.6 ± 0.38-4.5 ± 0.37-3.9 ± 0.38-4.3 ± 0.37-2.3 ± 0.37-1.2 ± 0.38

Adverse events

Collected over Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Baseline to Week 32) regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dupilumab 300 mg qw—1/63 (1.6%)35/63 (55.6%)
Dupilumab 300 mg q2w—2/64 (3.1%)34/64 (53.1%)
Dupilumab 200 mg q2w—1/61 (1.6%)34/61 (55.7%)
Dupilumab 300 mg q4w—3/65 (4.6%)39/65 (60%)
Dupilumab 100 mg q4w—5/65 (7.7%)38/65 (58.5%)
Placebo—4/61 (6.6%)38/61 (62.3%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
Dermatitis atopicSkin and subcutaneous tissue disorders0/631/640/610/654/651/61
TachycardiaCardiac disorders0/630/641/610/650/650/61
Hip dysplasiaCongenital, familial and genetic disorders0/630/640/610/650/651/61
Anaphylactic shockImmune system disorders0/630/641/610/650/650/61
OsteonecrosisMusculoskeletal and connective tissue disorders0/630/640/610/650/651/61
Respiratory failureRespiratory, thoracic and mediastinal disorders0/630/641/610/650/650/61
Abortion inducedSurgical and medical procedures0/630/640/610/650/651/61
Viral infectionInfections and infestations1/630/640/610/650/650/61
SyncopeNervous system disorders0/631/640/610/650/650/61
CellulitisInfections and infestations0/630/640/610/651/650/61
Most frequent other events
Showing 10 of 17
Most frequent other events
EventDupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlacebo
NasopharyngitisInfections and infestations16/6316/6416/6121/6520/6516/61
Dermatitis atopicSkin and subcutaneous tissue disorders8/6313/648/6110/6511/6510/61
Upper respiratory tract infectionInfections and infestations5/636/642/615/655/6511/61
HeadacheNervous system disorders8/635/649/615/657/652/61
Conjunctivitis allergicEye disorders3/632/646/613/651/652/61
Urinary tract infectionInfections and infestations0/633/646/613/652/652/61
Back painMusculoskeletal and connective tissue disorders2/632/640/612/653/655/61
Herpes simplexInfections and infestations1/632/643/611/655/650/61
Oral herpesInfections and infestations0/633/642/613/655/650/61
VomitingGastrointestinal disorders1/630/644/610/650/653/61

Baseline characteristics

Baseline population included safety analysis set (SAF) that included all randomized participants who received any investigational product and analyzed as treated. One participant randomized into Dupilumab 200 mg q2w arm was not treated and hence, excluded from the baseline population.

Age, Continuous
Age, Continuous(years)Dupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlaceboTotal
Mean36.2 ± 10.7439.4 ± 12.0635.8 ± 14.9036.8 ± 10.7736.6 ± 11.5537.2 ± 13.1037.0 ± 12.06
Sex: Female, Male
Sex: Female, Male(Participants)Dupilumab 300 mg qwDupilumab 300 mg q2wDupilumab 200 mg q2wDupilumab 300 mg q4wDupilumab 100 mg q4wPlaceboTotal
Female202325253121145
Male434136403440234
08

Study locations

84 sites
  • Birmingham, Alabama, United States
  • Mobile, Alabama, United States
  • Tucson, Arizona, United States
  • Bakersfield, California, United States
  • San Diego, California, United States
  • Santa Monica, California, United States
  • Jacksonville, Florida, United States
  • Ormond Beach, Florida, United States
  • Skokie, Illinois, United States
  • New Orleans, Louisiana, United States
  • Andover, Massachusetts, United States
  • Boston, Massachusetts, United States
  • Troy, Michigan, United States
  • Saint Louis, Missouri, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Winston-Salem, North Carolina, United States
  • Portland, Oregon, United States
  • Pittsburgh, Pennsylvania, United States
  • Johnston, Rhode Island, United States
  • Greer, South Carolina, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Seattle, Washington, United States
  • Vancouver (2 locations), British Columbia, Canada
  • Winnipeg, Manitoba, Canada
  • Barrie, Ontario, Canada
  • Hamilton, Ontario, Canada
  • Markham, Ontario, Canada
  • Oakville, Ontario, Canada
  • Peterborough, Ontario, Canada
  • Richmond Hill, Ontario, Canada
  • Waterloo, Ontario, Canada
  • Windsor, Ontario, Canada
  • St. Hyacinthe, Quebec, Canada
  • Quebec, Canada
  • Kutná Hora, Czechia
  • Nachod, Czechia
  • Praha, Czechia
  • Svitavy, Czechia
  • Usti nad Labem, Czechia
  • Augsburg, Germany
  • Baden, Germany
  • Berlin, Germany
  • Bonn, Germany
  • Dresden, Germany
  • Dülmen, Germany
  • Frankfurt/ Main, Germany
  • Frankfurt/Main, Hessen, Germany
  • Gera, Germany
  • Hamburg, Germany
  • Heidelberg, Germany
  • Kiel, Germany
  • Mahlow, Germany
  • Muenster, Germany
  • Munich, Germany
  • Osnabruck, Germany
  • Tübingen, Germany
  • Borsod-Abauj-Zemplen, Hungary
  • Budapest, Hungary
  • Kaposvár, Hungary
  • Szeged, Hungary
  • Szolnok, Hungary
  • Tolna, Hungary
  • Fukuoka, Japan
  • Hokkaido, Japan
  • Saitama, Japan
  • Tokyo, Bunkyo-ku, Japan
  • Tokyo, Chiyoda-ku, Japan
  • Tokyo, Nakano-ku, Japan
  • Tokyo, Nerima-ku, Japan
  • Tokyo, Shibuya-ku, Japan
  • Tokyo, Shinagawa-ku, Japan
  • Tokyo, Shinjuku-ku (2 locations), Japan
  • Tokyo, Suginami-ku (2 locations), Japan
  • Yokohama, Japan
  • Gdansk (2 locations), Poland
  • Katowice, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Poznan, Poland
  • Warsaw (2 locations), Poland
  • Wroclaw, Poland
09

References and documents

Publications

  • Thaci D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016 Jan 2;387(10013):40-52. doi: 10.1016/S0140-6736(15)00388-8. Epub 2015 Oct 8. PubMed 26454361 ↗
  • Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NM, Pirozzi G, Mastey V. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016 Mar;74(3):491-8. doi: 10.1016/j.jaad.2015.10.043. Epub 2016 Jan 14. PubMed 26777100 ↗
  • Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, Wu R, Ardeleanu M, Graham NMH, Pirozzi G, Sutherland ER, Mastey V. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2016 Sep;75(3):506-515. doi: 10.1016/j.jaad.2016.04.054. Epub 2016 Jun 4. PubMed 27268421 ↗
  • Silverberg JI, Simpson EL, Guttman-Yassky E, Cork MJ, de Bruin-Weller M, Yosipovitch G, Eckert L, Chen Z, Ardeleanu M, Shumel B, Hultsch T, Rossi AB, Hamilton JD, Orengo JM, Ruddy M, Graham NMH, Pirozzi G, Gadkari A. Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials. Dermatitis. 2021 Oct 1;32(1S):S81-S91. doi: 10.1097/DER.0000000000000698. PubMed 33165005 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of May 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 3 years 3 months after primary completion. A results delay was requested in Apr 2015.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2013
First posted
May 22, 2013
Start
May 2013
Primary completionActual
May 2014
CompletionActual
Sep 2014
Results delay requested
Apr 1, 2015
Results first posted
Aug 28, 2017
Last update
Aug 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01859988
Collaborators
Sanofi
Responsible party
Sponsor
First posted
May 22, 2013
Start date
May 2013
Primary completion
May 2014
Completion
Sep 2014
Results posted
Aug 28, 2017
Last update
Aug 28, 2017

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion